BCART Biocartis Group NV

Press news Biocartis Group NV: Biocartis Announces Market Release of SeptiCyte® RAPID test on Idylla™

Press news Biocartis Group NV: Biocartis Announces Market Release of SeptiCyte® RAPID test on Idylla™
EN
06/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biocartis Group NV

 PRESS RELEASE

Press release Biocartis Group NV: Biocartis Group NV provides an updat...

Press release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 09 May 2024, 07:00 CEST Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting Mechelen, Belgium, 09 May 2024 – Biocartis Group NV (the "Company") (Euronext Brussels: BCART), announces today that it has decided to postpone the publication of its 2023 Annual Report, in view of the ongoing preparation of the contem...

 PRESS RELEASE

Persbericht Biocartis Group NV: Biocartis Group NV brengt een update r...

Persbericht Biocartis Group NV: Biocartis Group NV brengt een update rond de publicatie van haar jaarverslag en de jaarlijkse algemene vergadering BIOCARTIS GROUP NV (Euronext Brussels: BCART) PERSBERICHT - GEREGULEERDE INFORMATIE - 09 mei 2024, 07:00 CEST Biocartis Group NV brengt een update rond de publicatie van haar jaarverslag en de jaarlijkse algemene vergadering Mechelen, België, 09 mei 2024 – Biocartis Group NV (de "Vennootschap") (Euronext Brussels: BCART), kondigt vandaag aan dat zij beslist heeft de publicatie van haar 2023 Jaarverslag uit te stellen, in het licht van de lopen...

 PRESS RELEASE

Press release Biocartis Group NV: Disclosure of transparency notificat...

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, of which an amended version was received on January 8, 2024, showing that...

 PRESS RELEASE

Press release Biocartis Group NV: Disclosure of transparency notificat...

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, showing that JPMorgan Chase & Co., with registered office a...

 PRESS RELEASE

Press release Biocartis Holdings Inc.: Recapitalization completed and ...

Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of Biocartis was completed last week, strengthening the balance sheet with a new investment of €40 million and a €132 million conversion of debt to equity.Product portfolio expansion with the launch of three breast cancer products: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with our partner APIS, the APIS Breast Cancer Subtyping...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch